Navigation Links
Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis
Date:12/1/2008

nts -- including examining other anti-inflammatory proteins for study purposes."

Complete abstinence from alcohol is the single most important treatment for alcoholic hepatitis. It's the only way to reverse liver damage or, in more advanced cases, to reduce the chance that the disease will become worse. Without abstinence, the majority of people with alcoholic hepatitis eventually develop cirrhosis and die, says Dr. Shah.

Mayo Clinic's Division of Gastroenterology and Hepatology has been ranked #1 in the U.S. News & World Report Honor Roll of Top Hospitals since the rankings began 18 years ago.

For more information on liver disease and alcoholic hepatitis, please visit http://www.mayoclinic.org/liver-disease/ and http://www.mayoclinic.com/health/alcoholic-hepatitis/DS00785.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , MORRISVILLE, N.C., Dec. 1 ...the investigation of devices for minimally-invasiv...the initiation of a feasibility clinical trial des...bined surgical and catheter procedure, the converg...roxysmal atrial fibrillation (AF). This prospecti...
(Date:12/1/2009)... , PISCATAWAY, N.J., Dec. 1 ...ens.com/hearing) a leading global manufacturer of ...rtnership with Quota International,s Sound Beginni...h September 2010. ,, As part of the renewed par...ide vouchers for 100 free hearing instruments to b...
(Date:12/1/2009)... , SAN DIEGO, Dec. 1 ...today announced that a new, recently completed pre... comparable toxicity of ANX-514 and Taxotere®...X,s partner for ANX-514 in South Korea, independen... "Our independent confirmation of the bioequivalen...
Breaking Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Surviving mass extinction by leading a double life 9262 1Surviving mass extinction by leading a double life 9262 2 2429 4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 9257 1 2429 4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 9257 2 2429 4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 9257 3 2429 4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 9257 4Nominate the Parentgivers of the Year 51654 1Nominate the Parentgivers of the Year 51654 2
...harmaceuticals Inc. announced today that data on C...im) will be presented at the 50th Annual Meeting o...cember 6-9, 2008 in San Francisco, California. , ... and hematology research centers will present data...orting important findings in leukemia-related diso...
...rporation,(Nasdaq: THOR ), a world leader in dev... to save, support and restore failing hearts, said...ta from its HeartMate II Destination,Therapy (DT) ...he device,achieved statistically superior outcomes...ted with the company,s HeartMate XVE. The DT study...
Other Medicine Technology:Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 2Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 3Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 4Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 5Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 6Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4
(Date:12/1/2009)...Dec. 1 Individuals in c...y than those with traditional coverage to exhibit ...ngaged in wellness programs, and to be more inclin...lding down costs, according to survey results rele...earch Institute (EBRI). ,, At the same time, t...
(Date:12/1/2009)...ec. 1 Abrazo Media Relations-- The... http:// www.pedsorthopaedics.com ) located in Mes...urgeon Dr. J. Hunt Udall to its practice. ,, D...edic surgery after recently completing his fellows...achusetts where he focused on adult and pediatric ...
(Date:12/1/2009)...DALE, Fla., Dec. 1 OrbusNeich toda...n the randomized clinical trial of the Combo Bio-e..., A prospective, randomized, multicenter study,... M inal sirolimus coat ED bio- E ngineered ...tes in Asia, Australia, Europe and South America ....
(Date:12/1/2009)... ADEAGies Foundation will honor The Forsyth Instit...ies Awards celebration to be held on February 27, ...010 ADEA Annual Session & Exhibition. The William ...ment recognize contributions to, and support of gl...complete listing of Gies Award winners, visit www...
(Date:12/1/2009)...alifornia are unable to successfully obtain inform...despite recent state legislation intended to impro..., Posing as low-income uninsured patients, resear...third of the hospitals they approached and the est...allowed under California law, according to the fin...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Hospital price transparancy laws in California fall short, study finds 2
.... 29 SAFC Pharma(TM), a focus,area within SAFC(R)...AL ),today announced details of a new suite that h...will produce high-potency active pharmaceutical,in...elivery molecules, including monoclonal antibodies...
...lif. Investigators at the Stanford University Sch...eversibly fine-tune the ,activity of individual pr...owerful new laboratory tool for identifying more ... cancer-fighting proteins are selectively delivere...
...quired for the earliest steps in embryonic develop...ories in the brains of adult animals, scientists h...e connections between brain cells, beta-catenin co...ctober issue of Nature Neuroscience . , The pro...
...imens would be more convenient and effective, rese...ay News) -- A vaccine that protects against the mi...eriod of time -- and with fewer injections -- coul...y a few injections and would offer longer-lasting ...
... The National Institutes of Health has ...o develop a red VCSEL array assembly for the reado...ar is developing the new technology for use in com... (PRWEB) September 28, 2008 -- NI...
...nish" fallen marathon runner,s race and raise fund...Massachusetts School of Pro..., September 28,for the seventh year in a row since...oston marathon, at the same time,raising funds for...
Other Medicine News:Health News:SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis 2Health News:SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis 3Health News:New way to control protein activity could lead to cancer therapies 2Health News:New way to control protein activity could lead to cancer therapies 3Health News:'Hub' of fear memory formation identified in brain cells 2Health News:'Hub' of fear memory formation identified in brain cells 3Health News:Studies Ignite Hope for Long-Acting Allergy Vaccines 2Health News:Studies Ignite Hope for Long-Acting Allergy Vaccines 3Health News:Studies Ignite Hope for Long-Acting Allergy Vaccines 4Health News:NIH Awards a Phase I Small Business Innovative Research Grant on "Novel Laser Scanning Technology for Computed Radiography" to VIXAR and iCRco 2Health News:MSPP Holds Seventh Annual 5K Lucero Memorial Run and Latino Mental Health Breakfast on Sunday, September 28, 2008 2Health News:MSPP Holds Seventh Annual 5K Lucero Memorial Run and Latino Mental Health Breakfast on Sunday, September 28, 2008 3
Mastisol Liquid Adhesive
...ue adhesive is indicated for the closure of topica... and trauma-induced lacerations in areas of low sk...nd have easily approximated skin edges. In vitro s...ive may act as a barrier to microbial penetration ...
Epiglu®
Marquette T-Wave Alternans (TWA) Analysis
Medicine Products: